## VTR: Ventas, Inc. - XLRE: Real Estate

### Executive Summary

No thesis match: MRS_10 -1.1% below STRENGTH zone (3.0-6.0%); PEG 1.74 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($77.53)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Natixis Buys New Holdings in Ventas, Inc. $VTR**
- Source: MarketBeat | 20251209T124610 | Somewhat-Bullish | Relevance: 99%
- Natixis has acquired a new position in Ventas, Inc. (NYSE:VTR), purchasing over 318,000 shares valued at approximately $20.14 million. This move comes as several analysts have upgraded Ventas with "Moderate Buy" ratings and target price increases. Despite this institutional interest, company insiders have been net sellers, with significant share sales by the CEO and other executives.

**2. Investment Management Corp of Ontario Boosts Holdings in Ventas, Inc. $VTR**
- Source: MarketBeat | 20251209T141545 | Somewhat-Bullish | Relevance: 99%
-  Investment Management Corp of Ontario significantly increased its stake in Ventas, Inc. by 1,019% in Q2, bringing its total holdings to 133,061 shares valued at approximately $8.4 million. This move is part of a broader trend of institutional investment, with firms collectively owning about 94% of Ventas stock. Despite recent insider selling and a high dividend payout ratio, analysts maintain a "Moderate Buy" rating for VTR, projecting an average target price of $78.40.

**3. Should Ventas’ (VTR) $500 Million Notes Issuance Require Action From Healthcare REIT Investors?**
- Source: Simply Wall Street | 20251208T062725 | Somewhat-Bullish | Relevance: 99%
-  Ventas (VTR) recently issued $500 million in 5.000% Senior Notes due 2036 to enhance financial flexibility and fund general corporate purposes, including potential debt repayment. This new debt, along with an upsized revolving credit facility, provides the company with the financial capacity to pursue its $2 billion acquisition pipeline in healthcare real estate. While analysts are optimistic, investors should consider how increased leverage and interest coverage constraints might impact Ventas's investment narrative.

**4. Jump Financial LLC Has $9.74 Million Stock Position in Ventas, Inc. $VTR**
- Source: MarketBeat | 20251209T120909 | Neutral | Relevance: 98%
-  Jump Financial LLC significantly increased its stake in Ventas, Inc. by 1,853.1% in Q2, bringing its total holdings to 154,237 shares valued at approximately $9.74 million. Despite a "Moderate Buy" consensus rating and analysts raising price targets, the stock trades near its average target, suggesting limited near-term upside. Insiders, including the CEO and CFO, have conducted substantial sales of their Ventas shares, even as institutional ownership remains high at 94.18%.

**5. Quantbot Technologies LP Acquires 27,738 Shares of Ventas, Inc. $VTR**
- Source: MarketBeat | 20251207T104140 | Somewhat-Bullish | Relevance: 98%
-  Quantbot Technologies LP significantly increased its stake in Ventas, Inc. (NYSE:VTR) by 1,108.6% in the second quarter, acquiring an additional 27,738 shares to own a total of 30,240 shares valued at $1.91 million. This move is part of broader institutional investor activity, with several other hedge funds also adjusting their positions in the real estate investment trust. Ventas has shown strong financial performance, reporting revenue up 20.5% year-over-year and beating EPS consensus, alongside a declared quarterly dividend.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Keybanc | $85 | $70 | +21% |
| 2025-11-25 | Wells Fargo | $88 | $80 | +10% |
| 2025-11-13 | Scotiabank | $80 | $74 | +8% |
| 2025-11-11 | Citigroup | $88 | $80 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Keybanc | main | Overweight |
| 2025-11-25 | Wells Fargo | main | Overweight |
| 2025-11-13 | Scotiabank | main | Sector Perform |
| 2025-11-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 17 ($4.24M) |
| Sells | 14 ($23.22M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 15.7% (+2.5%)
- JPMORGAN CHASE & CO: 12.7% (+102.6%)
- Blackrock Inc.: 11.1% (+2.6%)
- State Street Corpora: 6.2% (+3.3%)
- FMR, LLC: 5.7% (+12.1%)

### Key Risks

1. Heavy insider selling: $23M sold (14 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.74 elevated, pricing in significant growth expectations. Analyst sentiment positive (4 raises, avg +12%). Insider selling cluster ($23.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $37.6B |
| Beta | 0.79 |
| 52W Range | $56.68 - $81.86 |
| Short Interest | 3.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.74 |
| Forward P/E | 141.6 |
| Current P/E | 296.3 |
| YoY Growth | 109.3% |
| EPS Direction | FALLING |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 4.1pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.09% (CS: 48) | Neutral |
| RSI_14 | 64.6 | Neutral |
| MACD Histogram | -0.24 | Bearish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 1.168x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $80.01
- **Stop Loss:** $77.53 (3.1% risk)
- **Target:** $82.49 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 201
- **Position Value:** $16,082.01
- **Portfolio %:** 16.08%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not inverted—indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-11 (Est: $0.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.05 | $0.12 | +141.9% |
| 2025Q2 | $0.14 | $0.15 | +10.4% |
| 2025Q1 | $0.07 | $0.10 | +35.8% |
| 2024Q4 | $0.05 | $0.13 | +156.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*